Btk inhibitor 2 Clinical Trials

Size	Price	Qty
5mg	USD 127

Clinical Trials

Several clinical trials spanning Phase I, Phase II, and combined Phase I/II designs are evaluating BTK inhibition regimens across various hematologic malignancies, including mantle cell lymphoma, indolent B-cell lymphomas, aggressive B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Richter's syndrome. Collaborations involving academic institutions and pharmaceutical sponsors—such as BeiGene, Prelude Therapeutics, MorphoSys AG, and Incyte Corporation—encompass active recruiting trials focused on combinatorial strategies as well as studies currently in preparation prior to patient enrollment.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06029309	Not yet recruiting	Mantle Cell Lymphoma	Alvaro Alencar MD\|BeiGene\|Incyte Corporation\|MorphoSys AG\|University of Miami	2024-05-01	Phase 1\|Phase 2
NCT06350318	Recruiting	Follicular Lymphoma\|Marginal Zone Lymphoma\|B-Cell Lymphoma	H. Lee Moffitt Cancer Center and Research Institute\|BeiGene Ltd.	2024-03-13	Phase 2
NCT06067048	Not yet recruiting	Lymphoma	Stichting Hemato-Oncologie voor Volwassenen Nederland	2024-02-01	Phase 2
NCT05665530	Recruiting	Aggressive B-Cell Non-Hodgkin''s Lymphoma\|Aggressive B-Cell NHL\|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma (MCL)\|Richter''s Syndrome\|T-cell Lymphoma	Prelude Therapeutics\|BeiGene	2023-09-12	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Btk inhibitor 2 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Btk inhibitor 2 selectively binds to Bruton's tyrosine kinase, preventing its auto-phosphorylation and blocking downstream B-cell receptor signaling cascades, which leads to suppressed proliferation and induced apoptosis in malignant B lymphocytes. This targeted suppression of oncogenic survival pathways provides the pharmacological rationale for its clinical investigation in B-cell malignancies, such as mantle cell lymphoma and chronic lymphocytic leukemia.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).